42027-81-6

Basic information

• Product Name: 1-hydroxyethyl-4-nitropyrazole
• Synonyms: 1-hydroxyethyl-4-nitropyrazole;1-(2-Hydroxyethyl)-4-nitro-1H-pyrazole;1beta-Hydroxyethyl-4-nitropyrazole;M and B 4998;2-(4-Nitro-1H-pyrazol-1-yl)
• CAS NO: 42027-81-6
• Molecular Formula: C₅H₇N₃O₃
• Molecular Weight: 157.13
• Mol File: 42027-81-6.mol
• Article Data: 17

Chemical Properties

• Melting Point: 92-94℃
• Boiling Point: 343.5°C at 760 mmHg
• Flash Point: 161.6°C
• Appearance: /
• Density: 1.53
• Vapor Pressure: 2.67E-05mmHg at 25°C
• Refractive Index: 1.631
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-hydroxyethyl-4-nitropyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-hydroxyethyl-4-nitropyrazole(42027-81-6)
• EPA Substance Registry System: 1-hydroxyethyl-4-nitropyrazole(42027-81-6)

Safety Data

• Hazardous Substances Data: 42027-81-6(Hazardous Substances Data)

Usage

General Description

1-Hydroxyethyl-4-nitropyrazole is a chemical compound that belongs to the class of nitropyrazole derivatives. Its molecular structure consists of a pyrazole ring with a nitro group at the 4-position and a hydroxyethyl group attached to the nitrogen atom. 1-Hydroxyethyl-4-nitropyrazole has potential applications in various fields such as pharmaceuticals, agrochemicals, and materials science. It may also exhibit interesting properties such as biological activity and the ability to participate in various chemical reactions. Further research and development of 1-Hydroxyethyl-4-nitropyrazole may lead to the discovery of new applications and potential uses in different industries.

InChI:InChI=1/C5H7N3O3/c9-2-1-7-4-5(3-6-7)8(10)11/h3-4,9H,1-2H2

Upstream product

• 1333960-64-7 2-[4-(4-amino-6-methylpyrimidin-2-yl)piperazin-1-yl]ethanol 
• 1346672-86-3 1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-4-nitro-1H-pyrazole 
• 2075-46-9 4-nitro-1H-pyrazole 
• 540-51-2 2-bromoethanol 

Downstream Products

• 948570-75-0 1-(2-methoxyethyl)-4-nitro-1H-pyrazole 
• 948570-74-9 1-(2-methoxyethyl)-1H-pyrazole-4-amine 
• 1421856-75-8 C₂₂H₂₁F₂N₇O₃ 
• 1394161-75-1 5-m-tolyl-oxazole-4-carboxylic acid {1-[2-(4,6-dimethoxy-pyrimidin-2-yloxy)-ethyl]-1H-pyrazol-4-yl}-amide 
• 1394161-09-1 5-m-tolyl-oxazole-4-carboxylic acid {1-[2-(benzo[1,3]dioxol-5-yloxy)-ethyl]-1H-pyrazol-4-yl}-amide 
• 1394162-45-8 2-(4-(5-(m-tolyl)oxazole-4-carboxamido)-1H-pyrazol-1-yl)ethyl 4-methyl-benzenesulfonate 
• 1394162-44-7 2-(4-(5-(m-tolyl)oxazole-4-carboxamido)-1H-pyrazol-1-yl)ethyl methanesulfonate 
• 1394162-42-5 N-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)-5-(m-tolyl)oxazole-4-carboxamide 
• 948571-47-9 2-(4-amino-1H-pyrazol-1-yl)ethan-1-ol 

Relevant articles and documents

ARYL AND HETEROARYL-CARBOXAMIDE SUBSTITUTED HETEROARYL COMPOUNDS AS TYK2 INHIBITORS

Novel carboxamide substituted compounds of Formula (I) are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Tyrosine Kinase 2 (Tyk2).

Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis

Selective JAK3 inhibitors have been shown to have a potential benefit in the treatment of autoimmune disorders. Here we report the identification of a series of pyrazolopyrimidine derivatives as potent JAK3 inhibitors that exploit a unique cysteine (Cys909) residue in JAK3. Most of these compounds (13k, 13n and 13 t), displayed stronger anti-JAK3 kinase activity and selectivity than tofacitinib. Furthermore, the most active inhibitor 13t (IC50 = 0.1 nM), also exhibited favourable selectivity for JAK3 in a panel of 9 kinases which contain the same cysteine. In a series of cytokinestimulated cellular analysis, compound 13 t, could potently block the JAK3-STAT signaling pathway. Further biological studies, including cellular antiproliferative activity assays and a rat adjuvant-induced arthritis model for in vivo evaluation, also indicated its efficacy and low toxicity in the treatment of rheumatoid arthritis. The results of these experimental explorations suggested that 13t is a promising lead compound for the development of selective JAK3 inhibitor with therapeutic potential in rheumatoid arthritis.

Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors

Janus kinases (JAKs) play a key role in the proliferation, apoptosis and differentiation of immune cells, and JAKs are considered as an attractive target for the treatment of inflammatory and autoimmune diseases. Here we show the design and optimization of pyrimidine-4,6-diamine derivatives as selectivity JAK3 inhibitors. Compound 11e, which might interact with unique cysteine (Cys909) residue in JAK3, exhibited excellent JAK3 inhibitory activity (IC50 = 2.1 nM) and high JAK kinase selectivity. In cellular assay, 11e showed moderate potency inhibiting IL-2-stimulated T cell proliferation. The data supports the further development of novel JAKs inhibitors.